XenoPort Rallies Almost 70 percent on Drug Approval

XenoPort Inc. (XNPT) spiked 65 percent to $10.49 and rallied to $11.34 earlier, the most intraday since the shares were listed in June 2005, after the drugmaker and partner in commercialization GlaxoSmithKline Plc (GSK) won US approval to sell a new drug, Horizant, for restless legs syndrome [RLS]after more than a year of delays. The [...]
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.